Moderna (NASDAQ:MRNA) Price Target Lowered to $96.00 at UBS Group

Moderna (NASDAQ:MRNA) had its price target reduced by UBS Group from $108.00 to $96.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also issued reports on the company. Bank of America reissued an “underperform” rating and set a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Jefferies Financial Group reduced their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Piper Sandler restated an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $78.83.

Moderna Stock Performance

MRNA opened at $43.17 on Wednesday. Moderna has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $16.61 billion, a PE ratio of -7.42 and a beta of 1.60. The firm’s 50-day moving average price is $43.22 and its 200 day moving average price is $70.88.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the firm earned ($1.39) earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna will post -9.3 EPS for the current fiscal year.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 2,664 shares of company stock worth $115,210 in the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of large investors have recently bought and sold shares of the stock. Douglas Lane & Associates LLC lifted its position in shares of Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after acquiring an additional 298,715 shares in the last quarter. GAMMA Investing LLC raised its stake in Moderna by 31.9% in the 4th quarter. GAMMA Investing LLC now owns 3,173 shares of the company’s stock valued at $132,000 after purchasing an additional 768 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Moderna by 4.2% in the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock valued at $25,359,000 after purchasing an additional 15,218 shares in the last quarter. Inspire Trust Co. N.A. boosted its stake in shares of Moderna by 73.5% during the 3rd quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock worth $1,104,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in shares of Moderna by 1.4% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock worth $19,239,000 after buying an additional 3,978 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.